Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD
Authors:
Open Access
- 5 February 2015
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 58 (6) , 1160-1166
Abstract
In patients with diabetes, intensive glycaemic control reduces microvascular complications. However, severe hypoglycaemia frequently complicates intensive glycaemic control. Blood biomarkers that predict successful intensification of glycaemic control in patients with type 2 diabetes without the development of severe hypoglycaemia would advance patient care. In patients who received intensive treatment for type 2 diabetes from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, we hypothesised that insulin deficiency and islet autoantibodies would be associated with severe hypoglycaemia and failure to achieve near-normal glycaemia (HbA1c <6.0% [42 mmol/mol]).Keywords
This publication has 28 references indexed in Scilit:
- Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1cBMC Endocrine Disorders, 2013
- The clinical utility of C‐peptide measurement in the care of patients with diabetesDiabetic Medicine, 2013
- Increased Mortality of Patients With Diabetes Reporting Severe HypoglycemiaDiabetes Care, 2012
- Harmonization of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National Institute of Diabetes and Digestive and Kidney Diseases ConsortiaThe Journal of Clinical Endocrinology & Metabolism, 2010
- The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD studyBMJ, 2010
- Hypoglycaemia in Type 2 diabetesDiabetic Medicine, 2008
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and MethodsThe American Journal of Cardiology, 2007
- Severe Hypoglycemia Monitoring and Risk Management Procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) TrialThe American Journal of Cardiology, 2007
- Hypoglycemia in DiabetesDiabetes Care, 2003
- CLINICAL AND PATHOGENIC SIGNIFICANCE OF PANCREATIC-ISLET-CELL ANTIBODIES IN DIABETICS TREATED WITH ORAL HYPOGLYCÆMIC AGENTSThe Lancet, 1977